12 Recent Developments in Cell and Gene Therapy as of April 22, 2022
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. In public offering news, Massachusetts-based Selecta Biosciences has announced a $38.7 million public offering to continue developing ImmTOR, its antigen-specific immune tolerance platform. Leading the private financing news, Cambridge-based cell […]